The ESMO (European Society for Medical Oncology) Asia Congress 2022 will be held in Singapore during December 2-4. Eight innovations of Hansoh Pharma's innovative drug Ameile (aumolertinib mesilate tablets) will be presented at the congress, including six about trial data and two about excellent cases, which are expected to fill data gaps on the use of aumolertinib in several different populations.
At the congress, 13 clinical trials on EGFR-TKI will be presented by authors from mainland China, including eight innovations of aumolertinib, accounting for 61.5% of the total, which respectively showcase the latest progress in the use of high-dose brain metastasis therapy, high-dose rare mutation therapy and targeted combination radiotherapy for NSCLC. This further reflects the international oncology community's authoritative recognition of China's original research.
High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
Speakers: Yun Fan (Hangzhou, China), Zhejiang Cancer Hospital
Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Speakers: WenFeng Fang (Guangzhou, China)
Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study
Speakers: Jiayan Chen (Shanghai, China)
Real-world data of first-line treatment with aumolertinib for elderly EGFR+ NSCLC patients
Speakers: Haitao Zhang (Nanjing, China)
Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Speakers: Fang S. Cun (NAN JING, China)
Aumolertinib as second-line therapy in T790M-positive or-negative patients with EGFR-mutated non-small cell lung cancer (NSCLC): A retrospective study
Speakers: Hongying Lv (Qingdao, China)
Aumolertinib treatment in L858R patient with brain metastases: A long-term survival Case Report
Speakers: Ling Xin Feng (Qingdao, China)
Long-term Response to aumolertinib in NSCLC Harboring EGFR Mutation and High PD-L1 Expression: Case Report
Speakers: Wanwan Cheng (nanjing, China)
More information about the research results of aumolertinib to be presented at the 2022 ESMO Asia Congress is available at:
http://cslide.ctimeetingtech.com/asia2022/attendee/confcal_3/presentation/list?q
